ArriVent BioPharma, Inc. (AVBP:NASDAQ) closed at $21.00 on October 23, 2026, up 9.38% on the day. The stock trades 41.4% below its 52-week high of $35.83 and 84.9% above its 52-week low of $11.36. Over the past year, it gained 12.9%. ArriVent BioPharma, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, AVBP closed higher on 123 days (49%). Its best day was May 29, 2026 (+12.24%) and its worst was October 6, 2026 (-46.98%). The stock moved 10% or more in a single session 9 times.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
Find more stocks like AVBP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.